JP2004507460A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004507460A5 JP2004507460A5 JP2002501464A JP2002501464A JP2004507460A5 JP 2004507460 A5 JP2004507460 A5 JP 2004507460A5 JP 2002501464 A JP2002501464 A JP 2002501464A JP 2002501464 A JP2002501464 A JP 2002501464A JP 2004507460 A5 JP2004507460 A5 JP 2004507460A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- cop1
- use according
- medicament
- neuropathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20979900P | 2000-06-07 | 2000-06-07 | |
| US62021600A | 2000-07-20 | 2000-07-20 | |
| PCT/US2001/002118 WO2001093893A2 (en) | 2000-06-07 | 2001-01-22 | The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004507460A JP2004507460A (ja) | 2004-03-11 |
| JP2004507460A5 true JP2004507460A5 (cg-RX-API-DMAC7.html) | 2006-02-09 |
| JP4328090B2 JP4328090B2 (ja) | 2009-09-09 |
Family
ID=26904524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002501464A Expired - Fee Related JP4328090B2 (ja) | 2000-06-07 | 2001-01-22 | 神経細胞の保護療法におけるコポリマー1、関連ペプチドおよびポリペプチドならびにそれらによって処理されたt細胞の使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20020037848A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1294390B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4328090B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20030007397A (cg-RX-API-DMAC7.html) |
| CN (1) | CN100438906C (cg-RX-API-DMAC7.html) |
| AT (1) | ATE314860T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU783031B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2398277C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1105263T1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60116467T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1294390T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2256200T3 (cg-RX-API-DMAC7.html) |
| IL (2) | IL150801A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA02007109A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ520282A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2001093893A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| EP1098902A4 (en) | 1998-07-23 | 2002-07-24 | Yeda Res & Dev | TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
| CA2411536A1 (en) * | 2000-06-05 | 2001-12-13 | V. Wee Yong | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| US20020077278A1 (en) * | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| WO2002076503A1 (en) * | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| EP1459065B1 (en) | 2001-12-04 | 2010-07-28 | Teva Pharmaceutical Industries, Ltd. | Processes for the measurement of the potency of glatiramer acetate |
| US7351686B2 (en) * | 2001-12-06 | 2008-04-01 | Yeda Research And Development Co. Ltd. | Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides |
| WO2004060265A2 (en) * | 2003-01-07 | 2004-07-22 | Yeda Research And Development Co. Ltd. | Eye-drop vaccine containing copolymer 1 for therapeutic immunization |
| CN1886506B (zh) * | 2003-09-29 | 2012-05-30 | 中外制药株式会社 | 在nk细胞中表达的蛋白质 |
| WO2005032482A2 (en) * | 2003-10-03 | 2005-04-14 | Bayhill Therapeutics, Inc. | Treatment of demyelinating autoimmune disease with modified ordered peptides |
| CA2546077C (en) * | 2003-11-12 | 2016-07-05 | Yeda Research And Development Co. Ltd. | Vaccine and method for treatment of neurodegenerative diseases |
| DK1701730T3 (da) * | 2003-12-09 | 2013-11-25 | Yeda Res & Dev | Fremgangsmåde og vaccine omfattende copolymer 1 til behandling af psykiatriske forstyrrelser |
| CA2565819A1 (en) | 2004-05-07 | 2005-12-01 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| DK1799703T3 (da) | 2004-09-09 | 2010-04-19 | Teva Pharma | Fremgangsmåde til fremstilling af blandinger af polypeptider ved hjælp af oprenset hydrogenbromid |
| ES2541780T3 (es) * | 2004-11-29 | 2015-07-24 | Yeda Research And Development Co., Ltd. | Inducción de la neurogénesis y terapia con células madre en combinación con el Copolímero 1 |
| JP2009536157A (ja) | 2006-04-13 | 2009-10-08 | ペプチミューン,インコーポレイテッド | エピトープ透過性の指向された拡張を介した指向性配列ポリマー組成物の設計方法および合成方法 |
| WO2009040814A1 (en) | 2007-09-24 | 2009-04-02 | Hadasit Medical Research Services & Development Ltd | Use of copolymer 1 for treatment of muscular dystrophy |
| AP3467A (en) | 2007-10-16 | 2015-11-30 | Peptimmune Inc | Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes |
| WO2009063459A2 (en) * | 2007-11-13 | 2009-05-22 | Yeda Research And Development Co. Ltd | Synthetic peptide copolymers for treatment of neurodevelopmental disorders |
| RS55607B1 (sr) | 2009-08-20 | 2017-06-30 | Yeda Research & Development Company Ltd | Niskofrekventna terapija glatiramer acetatom |
| WO2011080733A1 (en) | 2010-01-04 | 2011-07-07 | Mapi Pharma Limited | Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8377885B2 (en) | 2010-01-04 | 2013-02-19 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| EA025780B1 (ru) | 2010-10-11 | 2017-01-30 | Тева Фармасьютикал Индастриз Лтд. | Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат |
| ES2601892T3 (es) | 2011-04-21 | 2017-02-16 | Mapi Pharma Limited | Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes |
| MX2014004309A (es) | 2011-10-10 | 2015-07-06 | Teva Pharma | Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer. |
| EP2892353A4 (en) | 2012-09-10 | 2016-10-26 | Yeda Res & Dev | INDIVIDUALIZED IMMUNOMODULATION THERAPY FOR NEURODEGENERATIVE ILLNESSES, CNS LESIONS AND AGGREGATIVE DEMENTIA |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| AU2017319728B2 (en) | 2016-08-31 | 2024-09-05 | Mapi Pharma Ltd | Depot systems comprising glatiramer acetate |
| IL316573A (en) | 2017-03-26 | 2024-12-01 | Mapi Pharma Ltd | Storage systems containing glatiramer acetate for the treatment of multiple sclerosis |
| EP4340853A4 (en) * | 2021-05-20 | 2025-05-07 | Washington University | Neuroprotective compositions and methods |
| KR20230128606A (ko) * | 2022-02-28 | 2023-09-05 | 경상국립대학교산학협력단 | 티로신을 유효성분으로 함유하는 알츠하이머병의 예방, 개선 또는 치료용 조성물 |
| CN121517513A (zh) * | 2025-11-20 | 2026-02-13 | 西湖大学 | 一种共聚物多肽及其药物组合物和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) * | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| IL113812A (en) * | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| JP2002503658A (ja) * | 1998-02-13 | 2002-02-05 | オートイミューン インク | COP−1及びTh−2促進性サイトカインを使用した、多発性硬化症の治療 |
-
2001
- 2001-01-22 DE DE60116467T patent/DE60116467T2/de not_active Expired - Lifetime
- 2001-01-22 NZ NZ520282A patent/NZ520282A/en not_active IP Right Cessation
- 2001-01-22 CA CA2398277A patent/CA2398277C/en not_active Expired - Lifetime
- 2001-01-22 JP JP2002501464A patent/JP4328090B2/ja not_active Expired - Fee Related
- 2001-01-22 WO PCT/US2001/002118 patent/WO2001093893A2/en not_active Ceased
- 2001-01-22 US US09/765,301 patent/US20020037848A1/en not_active Abandoned
- 2001-01-22 MX MXPA02007109A patent/MXPA02007109A/es active IP Right Grant
- 2001-01-22 ES ES01906632T patent/ES2256200T3/es not_active Expired - Lifetime
- 2001-01-22 KR KR1020027009275A patent/KR20030007397A/ko not_active Ceased
- 2001-01-22 CN CNB018065910A patent/CN100438906C/zh not_active Expired - Lifetime
- 2001-01-22 IL IL15080101A patent/IL150801A0/xx active IP Right Grant
- 2001-01-22 AT AT01906632T patent/ATE314860T1/de active
- 2001-01-22 AU AU34518/01A patent/AU783031B2/en not_active Expired
- 2001-01-22 EP EP01906632A patent/EP1294390B1/en not_active Expired - Lifetime
- 2001-01-22 DK DK01906632T patent/DK1294390T3/da active
-
2002
- 2002-07-18 IL IL150801A patent/IL150801A/en unknown
-
2006
- 2006-02-16 CY CY20061100219T patent/CY1105263T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hohlfeld et al. | The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis | |
| Bakalash et al. | Antigenic specificity of immunoprotective therapeutic vaccination for glaucoma | |
| JP2003520246A5 (cg-RX-API-DMAC7.html) | ||
| Schwartz | Macrophages and microglia in central nervous system injury: are they helpful or harmful? | |
| Mizrahi et al. | The tissue-specific self-pathogen is the protective self-antigen: the case of uveitis | |
| US9517256B2 (en) | Vaccine and method for treatment of neurodegenerative diseases | |
| CN100438906C (zh) | 共聚物1和相关肽和多肽及其处理过的t细胞在保护cns细胞避免谷氨酸毒性中的用途 | |
| Hendrix et al. | The role of T helper cells in neuroprotection and regeneration | |
| JP2003532618A5 (cg-RX-API-DMAC7.html) | ||
| HK1054507B (zh) | 共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途 | |
| Born et al. | Role of gammadelta T cells in protecting normal airway function | |
| TWI804521B (zh) | Tau胜肽免疫原結構 | |
| AU2007264682B2 (en) | Method of treatment of age-related macular degeneration | |
| JP2003518507A5 (cg-RX-API-DMAC7.html) | ||
| JP4542339B2 (ja) | 運動ニューロン疾患を治療するためのワクチン及び方法 | |
| CA2451521A1 (en) | Use of poly-glu, tyr for neuroprotective therapy | |
| He et al. | Glatiramer acetate reverses cognitive deficits from cranial-irradiated rat by inducing hippocampal neurogenesis | |
| JP5291878B2 (ja) | 治療的免疫のためのコポリマー1を含む点眼ワクチン | |
| PH12021552683A1 (en) | Heterologous administration of tau vaccines | |
| von Euler Chelpin et al. | Targets and mechanisms in prevention of Parkinson's disease through immunomodulatory treatments | |
| US20090191173A1 (en) | Induction Of Neurogenesis And Stem Cell Therapy In Combination With Copolymer 1 | |
| Palumbo et al. | Immunomodulation induced by central nervous system‐related peptides as a therapeutic strategy for neurodegenerative disorders | |
| García et al. | The severity of spinal cord injury determines the inflammatory gene expression pattern after immunization with neural-derived peptides | |
| Mantzourani et al. | Structural requirements for binding of myelin basic protein (MBP) peptides to MHC II: effects on immune regulation | |
| Wang et al. | Enhanced expression of neurotrophic factors in the injured spinal cord through vaccination with myelin basic protein-derived peptide pulsed dendritic cells |